Stamm

Stämm is reinventing biomanufacturing  from first principles with its pioneering BioProcessor - a continuous, laminar flow bioreactor designed to mimic nature's cellular environment. This patented microfluidic technology increasesbioprocess productivity sevenfold, reduces manufacturing footprint by 400x, and slashes CAPEX and OPEX costs.

Stamm's core innovation lies in its 3D-printed Bubble Free Bioreactor coupled with proprietary biocompatible materials and Stamm Caster design software. The company has also developed a cutting-edge biocompatible 3D printer with unmatched printing area and resolution.

Led by visionary co-founders Yuyo Llamazares and Federico D'Alvia Vegh, Stamm's interdisciplinary team executes with focus. Their solution addresses soaring antibody demand projected at $300B by 2025, contingent on scaling biomanufacturing capacity that traditional approaches cannot meet.

With pilot deals secured, strong revenue forecasts, and a vertical integration strategy, Stamm is poised to capitalize on the $4T biomanufacturing opportunity and drive the industry's evolution.